Hoth Therapeutics Inc. (HOTH) stock prices were down by 2.99% shortly after market trading commenced on September 8th, 2021. This brought the price per share down to USD$1.30 early on in the trading day.
Positive Phase 1b Results
September 8th, 2021 saw HOTH stock announce the completion of its safety results for Cohort 1 of its first in a human clinical trial. The trial is in regard to the company’s BioLexa platform. BioLexa is designed to treat atopic dermatitis, which is also known as eczema. The first cohort of the phase 1b trial enrolled healthy patients. These patients were administered topical BioLexa twice a day for 14 days as a part of the randomized, placebo-controlled trial.
HOTH Stock’s Trial Details
The primary endpoint of the two-part study is designed to evaluate the safety profile of the treatment. It will also characterize the pharmacokinetics of topical BioLexa Lotion. Preliminary efficacy data will be collected as a part of the cohort 2 phase with patients. No serious adverse events or drug-related treatment-emergent adverse events were observed during the execution of cohort 1. HOTH stock’s BioLexa trial is continuing on schedule, with the initiation of Cohort 2 expected soon for patients with mild to moderate atopic dermatitis.
About BioLexa
BioLexa has been patented as the company’s proprietary antimicrobial topical formulation is being developed for the treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities that are comprised of bacteria adhering to a surface (both biological and abiotic surfaces). The bacteria also adhere to other bacteria, as well as with a protective extracellular matrix. Maturation of bacterial biofilms have been shown to cause chronic and recurrent infections that are difficult to treat due to the barrier effect of the biofilm that facilitates antibiotic resistance and the avoidance of immune system mechanisms.
Scope of HOTH Stock’s Study
The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation. This ensures that bacteria are in a more susceptible state to antimicrobial therapies. The novel mechanisms of action at play have the potential to address and treat the broad clinical manifestations arising from Staphylococcal biofilm formation.
Future Outlook for HOTH Stock
HOTH stock reported a promising quarter, consolidated by the success of its positive Phase 1b results for its BioLexa platform. The company is keen to capitalize on the opportunities afforded to it as it continues to leverage the resources at its disposal. Current and potential investors are hopeful that this will facilitate significant and sustained increases in shareholder value.
